| CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer YS Chen, MJ Wu, CY Huang, SC Lin, TH Chuang, CC Yu, JF Lo PLoS One 6 (11), e28053, 2011 | 148 | 2011 |
| Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling MJ Wu, CI Jan, YG Tsay, YH Yu, CY Huang, SC Lin, CJ Liu, YS Chen, ... Molecular cancer 9, 1-16, 2010 | 137 | 2010 |
| Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression CC Chang, MJ Wu, JY Yang, I Carmarillo, CJ Chang Cancer Research, 2015 | 124 | 2015 |
| MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis CH Chao, CC Chang, MJ Wu, HW Ko, D Wang, MC Hung, JY Yang, ... The Journal of clinical investigation 124 (7), 3093-3106, 2014 | 121 | 2014 |
| Epithelial-Mesenchymal Transition Directs Stem Cell Polarity via Regulation of Mitofusin MJ Wu, YS Chen, MR Kim, CC Chang, S Gampala, Y Zhang, Y Wang, ... Cell Metabolism 29 (4), 993-1002, 2019 | 98 | 2019 |
| Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma MJ Wu, L Shi, J Dubrot, J Merritt, V Vijay, TY Wei, E Kessler, KE Olander, ... Cancer Discovery 12 (3), 812–835, 2022 | 58 | 2022 |
| The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer JE Berchuck, F Facchinetti, DF DiToro, I Baiev, U Majeed, S Reyes, ... Annals of Oncology 33 (12), 1269-1283, 2022 | 50 | 2022 |
| EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive CholangiocarcinomaCombination Treatment in FGFR2 Fusion Cholangiocarcinoma Q Wu, Y Zhen, L Shi, P Vu, P Greninger, R Adil, J Merritt, R Egan, MJ Wu, ... Cancer Discovery 12 (5), 1378–1395, 2022 | 40* | 2022 |
| Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCζ pathway MJ Wu, MR Kim, YS Chen, JY Yang, CJ Chang Oncogene 36 (22), 3193, 2017 | 40 | 2017 |
| Biology of IDH Mutant Cholangiocarcinoma MJ Wu, L Shi, J Merritt, AX Zhu, N Bardeesy Hepatology, 2022 | 27 | 2022 |
| The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity CK Baumgartner, H Ebrahimi-Nik, A Iracheta-Vellve, KM Hamel, ... Nature 622 (7984), 850-862, 2023 | 26 | 2023 |
| TET2 directs mammary luminal cell differentiation and endocrine response M Kim, MJ Wu, Y Zhang, JY Yang, CJ Chang Nature Communications 11, 4642, 2020 | 25 | 2020 |
| Active Component of Antrodia cinnamomea Mycelia Targeting Head and Neck Cancer Initiating Cells through Exaggerated Autophagic Cell Death CW Chang, CC Chen, MJ Wu, YS Chen, CC Chen, SJ Sheu, TW Lin, ... Evidence-Based Complementary and Alternative Medicine 2013, 2013 | 25 | 2013 |
| Regulation of microRNA-200c in cancer stem cells. MJ Wu, MR Kim, CJ Chang Oncoscience 2 (9), 745-746, 2015 | 7 | 2015 |
| SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers L Shi, W Shen, MI Davis, K Kong, P Vu, SK Saha, R Adil, J Kreuzer, ... Nature Cancer 4 (3), 365-381, 2023 | 6 | 2023 |
| High Fat Diet-induced Breast Cancer Model in Rat. MJ Wu, CJ Chang Bio-protocol 6 (13), e1852, 2016 | 5 | 2016 |
| Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer Y Zhang, MJ Wu, WC Lu, YC Li, CJ Chang, JY Yang Cell Metabolism 36 (1), 193-208, 2024 | 3 | 2024 |
| Regulation of Epithelial Plasticity and Cancer Stemness via MicroRNAs MJ Wu, YS Chen, MR Kim, CJ Chang Journal of Molecular and Genetic Medicine 10 (2), 2016 | 2 | 2016 |
| Immunometabolism at the crossroads of obesity and cancer—a Keystone Symposia report J Cable, JC Rathmell, EL Pearce, PC Ho, MC Haigis, MR Mamedov, ... Annals of the New York Academy of Sciences 1523 (1), 38-50, 2023 | 1 | 2023 |
Yu-Syuan ChenYang-Ming University在 ym.edu.tw 的電子郵件地址已通過驗證
